This transaction will expand NEOGEN's capabilities within the expanding $12B+ retail veterinary parasiticides market, aligns with the company's Animal Safety business segment, and much more.
NEOGEN Corporation has recently announced its acquisition of Atlanta-based CAPInnoVet, Inc, a companion animal health company that provides pet medications to the veterinary market. This transaction will offer NEOGEN entry into the evolving $12B+ retail parasiticide market.
“The acquisition of CAPInnoVet provides NEOGEN a strategic pathway into the parasiticide market and naturally aligns within our Animal Safety business segment,” said Doug Jones, COO of NEOGEN, in a company release. “We are excited for the team at CAPInnoVet to join the NEOGEN family.”
Founded in 2014, CAPInnoVet is a key provider of differentiated companion animal health products, granting better access to high-quality pet medications.
Additionally, CAPInnoVet will integrate into NEOGEN’s Animal Safety business segment, which includes veterinary instruments, pharmaceuticals, vaccines, and diagnostic products.
“We are very excited to be joining the NEOGEN team. Becoming a part of NEOGEN will allow us to not only further advance our vision of providing high-quality pet medications at a significant value to pet owners but also join a company that has similar values,” said Rudy Hauser, CAPInnoVet cofounder and CEO.
“I would like to thank the CAPInnoVet team for their commitment and dedication to making this company a success. We are extremely appreciative of their contributions; we certainly would not have been this successful without them, and for that, we are deeply grateful,” Hauser added.
The terms of the agreement were not disclosed.